Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”
Rhea-AI Summary
Lexicon Pharmaceuticals (NASDAQ: LXRX) published a white paper titled “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain” summarizing findings from an October 2025 Roundtable of patients, clinicians, advocates, and other stakeholders.
The paper highlights that chronic pain affects one in four American adults, costs the U.S. >$720 billion annually (including ~$190 billion in lost productivity), and calls for swift policy action to expand access to novel non-opioid therapies, citing the recently introduced Relief of Chronic Pain Act.
Positive
- None.
Negative
- None.
Details
News Market Reaction – LXRX
In the Jan 9 session, LXRX declined 0.85%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Annual pain cost
- more than $720 billion
- Total annual cost of chronic pain in the United States
- Lost productivity
- $190 billion
- Estimated annual lost worker productivity from chronic pain
- High-impact pain patients
- more than 20 million people
- Americans with high-impact chronic pain
- Americans with chronic pain
- more than 60 million Americans
- People living with chronic pain in the United States
- Current share price
- $1.18
- Pre-news price level for LXRX
- 52-week range
- $0.2836–$1.66
- LXRX 52-week low and high prior to this article
- Market cap
- $425,176,666
- LXRX market capitalization before this news
- 200-day MA
- $1.04
- LXRX 200-day moving average ahead of this announcement
Historical Context
-
Announcement of J.P. Morgan Healthcare Conference presentation and webcast availability.
-
Preclinical ACSL5 data reinforcing rationale for LX9851 and Novo Nordisk license.
-
Upcoming presentation of sotagliflozin adipose distribution data in HFpEF patients.
-
Participation in two December 2025 investor conferences with webcast access.
-
Jefferies London Healthcare Conference fireside chat announcement and webcast link.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
non-opioid medical
Medicare regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
-White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies-
-Need for swift action by policymakers to support millions of Americans suffering from chronic pain-
THE WOODLANDS, Texas, Jan. 09, 2026 (GLOBE NEWSWIRE) -- In October 2025, Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) convened an in-person Roundtable in Washington, D.C., to better understand the unmet needs of people living with chronic pain and identify what more can be done to benefit patients and society at large. The White Paper summarizing the findings, titled “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain,” is available as a free download here.
Chronic pain affects one in four American adults and is one of the leading causes of disability, driving direct medical spending, disability claims, and lost productivity each year. Chronic pain costs the United States more than
The Relief of Chronic Pain Act, recently introduced in the U.S. Senate, would ensure Medicare coverage for non-opioid medications specifically indicated for certain chronic pain conditions. It would also reduce or eliminate several barriers that often block timely access to needed care.
“We are exploring with partners how to add chronic pain to the legislative agenda, and how to help policymakers and payers prioritize new methods of pain relief,” said Mike Exton, Ph.D., Lexicon’s chief executive officer and director. “We believe that non-opioid treatments are going to be incredibly important, not only for the patient, but for society at large.”
Achieving meaningful progress will require a coalition of patients, caregivers, clinicians, patient advocacy groups, professional societies, and others. Swift action to expand access to safe, effective, non-opioid treatments for the more than 60 million Americans living with chronic pain is necessary to achieve progress.
Chronic pain does not discriminate based on demographics and political viewpoints. It affects rural, suburban, and urban communities alike. It impacts every generation. Addressing it must be a bipartisan, nationwide effort—one that reflects the best of what America can accomplish.
Click here to download “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visit www.lexpharma.com.
References
1Guy GP Jr, et al. Economic costs of chronic pain—United States, 2021. Med Care. 2025 Sep. Available from: https://pubmed.ncbi.nlm.nih.gov/40730349/
For Investor and Media Inquiries
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.